bullish

Daiichi Sankyo (4568 JP) – We like the Focus on Oncology but Look for a Better Entry Point

211 Views02 May 2024 12:00
Daiichi Sankyo has increased focus on high growth oncology and entered into a potentially very lucrative deal with Merck. We like the company, we like the focus, but the valuation concerns us.
What is covered in the Full Insight:
  • Overview of Japan's Oncology Market
  • Transformation of Daiichi Sankyo
  • Focus on Oncology
  • Agreements and Partnerships
  • Earnings Outlook and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
x